Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer

/PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II SBIR Contract from the...

Related Keywords

Boston ,Massachusetts ,United States ,Manijeh Goldberg ,Prnewswire Privo Technologies Inc ,Privo Technologies Inc ,National Cancer Institute ,Department Of Health ,Human Services ,National Institutes Of Health ,National Institutes ,Privo Technologies ,Disruptive Innovation In Drug Delivery ,